Breaking News
Sort by:
Top Post
Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and […]
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 for Prader-Willi Syndrome
Acadia Pharmaceuticals today announced the addition of a new Phase 3 development candidate to its […]
Heligenics Unveils A First-Of-Its-Kind Precision Prescription Test For Breast Cancer Therapeutics
Heligenics, a cutting-edge biotech company, announces a first-of-its-kind precision genetic test to select among drugs […]
Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)--The World's First Oral Epothilone Anti-Cancer Drug
Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals which is a synthetic biology-driven biopharma […]
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
Lantern Pharma, an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary […]
FDA Advisory Committee Votes Unanimously to Confirm Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Early Alzheimer's Disease
BioArctic AB‘s partner Eisai announced that the US Food and Drug Administration’s (FDA) Peripheral and […]
Gilteritinib as Maintenance Therapy Demonstrated Benefit in Subgroups of FLT3-ITD Acute Myeloid Leukemia Patients
Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) has presented […]
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
Astellas Pharma and Kate Therapeutics have announced an exclusive license agreement to develop and commercialize KT430. […]
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals and CRISPR Therapeutics today announced that the United States Food and Drug Administration (FDA) […]
Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
Rocket Pharmaceuticals, a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic […]
GSK Receives US FDA File Acceptance for Jemperli (dostarlimab) plus Chemotherapy for the Treatment of dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
GSK has announced the US Food and Drug Administration (FDA) accepted the supplemental Biologics License […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more